VistaGen Therapeutics analyst ratings
VistaGen Therapeutics analyst ratings
While ratings are subjective and will change, the latest VistaGen Therapeutics (VTGN) rating was a downgraded with a price target of $0.00 to $0.00. The current price VistaGen Therapeutics (VTGN) is trading at is $0.18, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/26/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 07/22/2022 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 05/20/2021 | 4981.87% | Baird | → $9 | Initiates Coverage On | → Outperform |
| 02/18/2021 | 3287.92% | Jefferies | → $6 | Initiates Coverage On | → Buy |
| 01/04/2021 | — | William Blair | Upgrades | Market Perform → Outperform | |
| 10/08/2020 | 3287.92% | Aegis Capital | → $6 | Initiates Coverage On | → Buy |
| 08/28/2019 | — | William Blair | Initiates Coverage On | → Outperform | |
| 07/22/2019 | 295.26% | Chardan Capital | $22 → $0.7 | Downgrades | Buy → Neutral |
| 06/27/2018 | 3287.92% | Maxim Group | → $6 | Initiates Coverage On | → Buy |
| 05/24/2018 | 3287.92% | Oppenheimer | → $6 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析师事务所 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 07/26/2022 | — | Maxim 集团 | 降级 | 买入 → 持有 | |
| 07/22/2022 | — | 威廉布莱尔 | 降级 | 跑赢大盘 → 市场表现 | |
| 2021 年 5 月 20 日 | 4981.87% | 贝尔德 | → 9 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2021 年 2 月 18 日 | 3287.92% | 杰富瑞集团 | → 6 美元 | 启动覆盖范围开启 | → 购买 |
| 01/04/2021 | — | 威廉布莱尔 | 升级 | 市场表现 → 跑赢大盘 | |
| 2020 年 8 月 10 日 | 3287.92% | 宙斯盾资本 | → 6 美元 | 启动覆盖范围开启 | → 购买 |
| 08/28/2019 | — | 威廉布莱尔 | 启动覆盖范围开启 | → 跑赢大盘 | |
| 07/22/2019 | 295.26% | 查丹资本 | 22 美元 → 0.7 美元 | 降级 | 买入 → 中性 |
| 2018 年 6 月 27 日 | 3287.92% | Maxim 集团 | → 6 美元 | 启动覆盖范围开启 | → 购买 |
| 05/24/2018 | 3287.92% | 奥本海默 | → 6 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
VistaGen Therapeutics Questions & Answers
VistaGen Therapeutics 问答
The latest price target for VistaGen Therapeutics (NASDAQ: VTGN) was reported by Maxim Group on July 26, 2022. The analyst firm set a price target for $0.00 expecting VTGN to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
美心集团于2022年7月26日公布了VistAgen Therapeutics（纳斯达克股票代码：VTGN）的最新目标股价。该分析公司将目标股价设定为0.00美元，预计VTGN将在12个月内降至0.00美元（可能下跌-100.00％）。去年有两家分析公司公布了评级。
The latest analyst rating for VistaGen Therapeutics (NASDAQ: VTGN) was provided by Maxim Group, and VistaGen Therapeutics downgraded their hold rating.
VistaGen Therapeutics（纳斯达克股票代码：VTGN）的最新分析师评级由Maxim集团提供，VistaGen Therapeutics下调了其持有评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of VistaGen Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for VistaGen Therapeutics was filed on July 26, 2022 so you should expect the next rating to be made available sometime around July 26, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与VistaGen Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。VistaGen Therapeutics的最新评级是在2022年7月26日发布的，因此您应该预计下一个评级将在2023年7月26日左右公布。
While ratings are subjective and will change, the latest VistaGen Therapeutics (VTGN) rating was a downgraded with a price target of $0.00 to $0.00. The current price VistaGen Therapeutics (VTGN) is trading at is $0.18, which is out of the analyst's predicted range.
尽管评级是主观的，并将发生变化，但最新的VistaGen Therapeutics（VTGN）评级下调，目标股价为0.00美元至0.00美元。VistaGen Therapeutics（VTGN）目前的交易价格为0.18美元，超出了分析师的预测区间。
